Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley
Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...
Yahoo Finance24d
Metagenomi Announces New Appointment to its Board of Directors
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...
ETF Daily News26d
Intellia Therapeutics’ (NTLA) “Neutral” Rating Reiterated at Wedbush
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for ...
Morningstar22d
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
EMERYVILLE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...